Darren Incorvaia - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Darren Incorvaia's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Darren Incorvaia
Verified
Staff Writer, Fierce Biotech
Berkeley
Beats
literature, media ethics education,gender foia, health guns, texas politics, higher education
None yet
Content
By Darren Incorvaia Verified| Fierce Biotech Verified An “inverse vaccine” that delivers deactivated allergens to the liver was able to reduce reactions in mice with allergic asthma for at least a year after treatment. Should the approach translate to humans, people with allergies may one day be able to take a vaccine that protects them from dangerous allergic reactions.
By Darren Incorvaia Verified| Fierce Biotech Verified CenExel is the latest CRO to change ownership hands. Boston-based private equity firm BayPine has acquired a majority stake in the company, leaving former majority owner Webster Equity Partners with a minority stake. BayPine did not disclose the financial details of the acquisition but said in an April 14 release that the transaction is expected to close in the second quarter of 2025.
By Darren Incorvaia Verified| Fierce Biotech Verified The Trump administration is freezing more than $2.2 billion in funding to Harvard University after the school defied the administration’s demands for radical change at the university. “The joint task force to combat anti-Semitism is announcing a freeze on $2.2 billion in multi-year grants and $60 million in multi-year contract value to Harvard University,” the Department of Health and Human Services said in an April 14 statement.
Company Info
Fierce Biotech
Berkeley, United States